MTOR and capillary hemangioma: The last decade has been marked by the use of highly efficacious beta‐blockers for infantile hemangiomas (IHs) and by the growing interest of mammalian target of rapamycin (mTOR) inhibitors in various aggressive vascular anomalies with slow‐flow and/or partial lymphatic differentiation.